Clinical trials - Press Releases

Date	Title	Company
30-Apr-2021	VFMCRP announces positive results of phase-III clinical trial of Velphoro® in China	Vifor Fresenius Medical Care Renal Pharma (VFMCRP)
29-Apr-2021	Oxford Immunotec’s T-SPOT Discovery SARS-CoV-2 Test Used in DIRECT study to Investigate the T Cell Response and COVID vaccination in Ethnic Minority Groups.	Oxford Immunotec
29-Apr-2021	Panthera becomes the world’s first clinical trial site to administer Valneva’s inactivated COVID-19 vaccine (VLA2001) to volunteers in phase 3 study	Panthera
29-Apr-2021	Interim Analysis from the Ongoing Open-Label Phase III Extension Study Shows Sustained Benefits of PXT3003 for Patients with Charcot-Marie-Tooth Disease Type 1A (‘CMT1A’)	Pharnext SA
29-Apr-2021	Vifor Pharma and Angion announce completion of enrollment in phase-II study of ANG-3777 for cardiac-surgery associated acute kidney injury	Vifor Pharma
29-Apr-2021	HUTCHMED Initiates Phase II Registration Study of HMPL 689 in Patients with Follicular Lymphoma and Marginal Zone Lymphoma in China	HUTCHMED
29-Apr-2021	Panthera becomes the world’s first clinical trial site to administer Valneva’s inactivated COVID-19 vaccine (VLA2001) to volunteers in phase 3 study	Panthera
28-Apr-2021	ViroCell, the UK’s first clinical trial focused viral vector manufacturer, announces its official launch	ViroCell
28-Apr-2021	Amgen Provides Updated Information On LUMAKRAS™ (Sotorasib)¹ Dose Comparison Study	Amgen
28-Apr-2021	Nirsevimab demonstrated protection against respiratory syncytial virus disease in healthy infants in Phase 3 trial	Sanofi
28-Apr-2021	ReiThera Completes Enrolment of Subjects in the Phase 2 Part of the Phase 2/3 Clinical Trial of its GRAd-COV2 Vaccine Candidate against COVID-19	ReiThera Srl
27-Apr-2021	Oxford Immunotec’s T-SPOT Discovery SARS-CoV-2 Test is Used in UK Com-COV Clinical Trial to Investigate the T Cell Response in Different Combinations of Approved COVID-19 Vaccines for the First and Second Doses	Oxford Immunotec
27-Apr-2021	SIFI Initiates Patient Enrollment in Phase II Trial evaluating Pro-ocular in Dry Eye Disease	SIFI SpA
27-Apr-2021	Nirsevimab demonstrated protection against respiratory syncytial virus disease in healthy infants in Phase 3 trial	Sanofi
26-Apr-2021	Nirsevimab MELODY Phase III trial met primary endpoint of reducing RSV lower respiratory tract infections in healthy infants	AstraZeneca
26-Apr-2021	Nirsevimab demonstrated protection against respiratory syncytial virus disease in healthy infants in Phase 3 trial	Sanofi
23-Apr-2021	Avillion’s positive Phase 2 trial of tri-specific Nanobody® sonelokimab (M1095) in chronic psoriasis published in The Lancet	Avillion LLP
23-Apr-2021	First patients dosed in three dermatology trials evaluating Fasenra in bullous pemphigoid, atopic dermatitis and chronic spontaneous urticaria	AstraZeneca
23-Apr-2021	Registration Opens for SMi's Aseptic Processing Conference 2021	SMi Group
23-Apr-2021	Revenue and growth forecasts from 2021 to 2031 for the Global Clinical Trial Supplies Market	VIsiongain Limited